Meridian Investment Counsel’s Intellia Therapeutics NTLA Stock Holding History

Meridian Investment Counsel’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-10,000	Closed	-$210K	–	184
2020 Q2	$210K	Hold	10,000	–	–	0.11%	159
2020 Q1	$122K	Hold	10,000	–	–	0.08%	159
2019 Q4	$147K	Hold	10,000	–	–	0.07%	179
2019 Q3	$134K	Hold	10,000	–	–	0.07%	169
2019 Q2	$164K	Hold	10,000	–	–	0.09%	169
2019 Q1	$171K	Hold	10,000	–	–	0.1%	170
2018 Q4	$136K	Hold	10,000	–	–	0.09%	157
2018 Q3	$286K	Hold	10,000	–	–	0.16%	138
2018 Q2	$274K	Hold	10,000	–	–	0.15%	141
2018 Q1	$211K	Hold	10,000	–	–	0.12%	163
2017 Q4	$192K	Hold	10,000	–	–	0.1%	175
2017 Q3	$248K	Hold	10,000	–	–	0.14%	151
2017 Q2	$160K	Hold	10,000	–	–	0.1%	167
2017 Q1	$141K	Buy	+10,000	New	+$134K	0.09%	171

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Meridian Investment Counsel's NTLA Position: Q3 2020 in Review

Meridian Investment Counsel sold out of Intellia Therapeutics (NTLA) in Q3 2020, closing a stake of 10,000 shares — an estimated $210K sold.

Meridian Investment Counsel first reported a position in NTLA in Q1 2017 and held it in 14 quarters. The position peaked at $286K in Q3 2018. 165 funds tracked by Wall St. Rank hold NTLA as of Q3 2020.

Meridian Investment Counsel reported no remaining Intellia Therapeutics position as of Q3 2020 after selling out during the quarter.
Meridian Investment Counsel sold 10,000 Intellia Therapeutics shares in Q3 2020, an estimated $210K.
Meridian Investment Counsel first reported a position in Intellia Therapeutics in Q1 2017 and held it in 14 quarters.
Meridian Investment Counsel's Intellia Therapeutics position peaked at $286K in Q3 2018.
165 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2020.

Based on Meridian Investment Counsel's 13F filing for Q3 2020, filed 23 Oct 2020.